Published in J Am Soc Nephrol on April 28, 2011
Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med (2012) 2.62
Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol (2013) 1.23
The regenerative potential of parietal epithelial cells in adult mice. J Am Soc Nephrol (2014) 1.02
Obesity in CKD--what should nephrologists know? J Am Soc Nephrol (2013) 0.98
Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. J Clin Endocrinol Metab (2012) 0.97
Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort. BMC Nephrol (2015) 0.89
Differential diagnosis of glomerular disease: a systematic and inclusive approach. Am J Nephrol (2013) 0.81
Influence of dietary protein on glomerular filtration before and after bariatric surgery: a cohort study. Am J Kidney Dis (2013) 0.80
Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy. Diabetes Metab J (2015) 0.80
Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study. BMC Endocr Disord (2013) 0.79
Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol (2013) 0.78
REIN on obesity, proteinuria and CKD. J Am Soc Nephrol (2011) 0.78
Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study. Am J Nephrol (2016) 0.75
Consequences of morbid obesity on the kidney. Where are we going? Clin Kidney J (2016) 0.75
Obesity and kidney disease: Hidden consequences of the epidemic. Indian J Nephrol (2017) 0.75
Obesity and kidney disease: hidden consequences of the epidemic. Pediatr Nephrol (2017) 0.75
Increased body mass index is a risk factor for end-stage renal disease in the Chinese Singapore population. Kidney Int (2017) 0.75
Hypertension in pediatric patients with chronic kidney disease: management challenges. Int J Nephrol Renovasc Dis (2017) 0.75
Obesity and kidney disease: hidden consequences of the epidemic. Clin Kidney J (2017) 0.75
Obesity and risk of death or dialysis in younger and older patients on specialized pre-dialysis care. PLoS One (2017) 0.75
Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Kidney Dis (Basel) (2017) 0.75
Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med (2007) 12.55
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health (2009) 9.79
Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56
Obesity and risk for chronic renal failure. J Am Soc Nephrol (2006) 3.67
Weight loss and the renin-angiotensin-aldosterone system. Hypertension (2005) 2.58
Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int (2004) 2.44
Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol (2007) 2.25
The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med (1981) 2.05
Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol (2006) 1.93
Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis (2008) 1.92
Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int (2006) 1.87
Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2009) 1.86
Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens (2002) 1.24
Body mass index is associated with altered renal hemodynamics in non-obese healthy subjects. Kidney Int (2004) 1.22
Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab (1982) 1.09
Obesity and renal hemodynamics. Contrib Nephrol (2006) 1.07
The epidemic of renal disease--what drives it and what can be done? Nephrol Dial Transplant (2006) 0.95
Obesity and CKD: how to assess the risk? Am J Kidney Dis (2008) 0.82
[Obesity: what impact on renal function?]. Rev Med Suisse (2006) 0.81
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Long-term outcome of renal transplantation from older donors. N Engl J Med (2006) 5.10
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med (2002) 3.57
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Hemolytic uremic syndrome. J Am Soc Nephrol (2005) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
QUality European STudies (QUEST)--a step forward in the quality of RRT care. Nephrol Dial Transplant (2005) 2.73
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol (2002) 2.46
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int (2008) 2.38
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet (2004) 2.38
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol (2006) 2.27
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol (2012) 2.26
Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis (2002) 2.25
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int (2004) 2.19
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis (2006) 2.17
Detection of pulmonary congestion by chest ultrasound in dialysis patients. JACC Cardiovasc Imaging (2010) 2.16
Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol (2010) 2.15
Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 2.12
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet (2002) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl (2005) 2.10
Rituximab for idiopathic membranous nephropathy. Lancet (2002) 2.03
Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol (2007) 2.02
Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation (2002) 2.02
The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis (2006) 2.01
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol (2005) 1.99
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl (2005) 1.96
When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant (2013) 1.95
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int (2003) 1.91
Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol (2008) 1.89
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89